A Phase 3 Multicenter, Randomized, Double-Masked, Sham controlled Clinical Trial To Assess The Safety And Efficacy Of Intravitreal Administration Of Zimura™ (Complement C5 Inhibitor) In Patients With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 448 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Masking Description: | Participant, “Evaluating” Investigator, Reading Center Personnel, and Sponsor Personnel are masked |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration |
| Actual Study Start Date : | June 29, 2020 |
| Estimated Primary Completion Date : | July 2022 |
| Estimated Study Completion Date : | July 2023 |
